Afra Janarious, MD
Neuromuscular Medicine · Orlando, FLNPI 1760826580
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Novo Nordisk at 22.9% of the total. Reporting peaked in 2022 at $292 and has fallen 77.6% since, to $66 in 2025.
Across 12 payments — averaging $37.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$103
- Alnylam Pharmaceuticals Inc.$95
- AbbVie$79
- Averitas Pharma Inc.$66
- Pfizer$63
- Amgen$33
- plus $11 from 1 others
What the payments were for
- Food & beverage$43797%
- Education$113%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 1 | $103 |
| Alnylam Pharmaceuticals Inc. | 1 | $95 |
| AbbVie(2 entities) | 4 | $79 |
| Averitas Pharma Inc. | 1 | $66 |
| Pfizer | 3 | $63 |
| Amgen | 1 | $33 |
| Biogen | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$103
How this compares
Too few neuromuscular medicine providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neuromuscular medicine in Orlando
- Amparo GutierrezOrlando$810K
- Manisha KorbWest Palm Beach$328K
- Michael Rosario-PrietoSt Petersburg$167K
- James WymerGainesville$33K
- Cole LinvilleJacksonville$32K
- Michael TodincaJacksonville Beach$16K
- Sara HuserWest Palm Beach$9K
- Naga Lakshmana NidadavoluSaint Cloud$9K
- Nathan CarberryMiami$5K
- Clifton GoochTampa$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.